Skip to main content
Clinical Trials/NCT05133258
NCT05133258
Completed
Not Applicable

Measuring Antibiotic Solution Concentration at the Tympanic Membrane Following Self-administration by Patients With Chronic Suppurative Otitis Media

Dartmouth-Hitchcock Medical Center1 site in 1 country3 target enrollmentJuly 5, 2022

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Chronic Suppurative Otitis Media
Sponsor
Dartmouth-Hitchcock Medical Center
Enrollment
3
Locations
1
Primary Endpoint
Concentration of Ciprofloxacin
Status
Completed
Last Updated
2 years ago

Overview

Brief Summary

The study team aims to elucidate the potential role of ototopical antibiotic concentration on outcomes in patients diagnosed with chronic suppurative otitis media (CSOM). Chronic suppurative otitis media (CSOM) is characterized by chronic inflammation of the middle ear with persistent discharge from a non-intact tympanic membrane. CSOM is notably associated with a significant burden of disease worldwide. Topical fluoroquinolones are first line therapy for CSOM and are advantageous as compared to oral or intravenous therapy in that these antibiotics avoid systemic side effects and have the potential to locally deliver high antibiotic concentrations, which were thought to be sufficient to overcome all bactericidal resistance to fluoroquinolones.

The investigators will measure antibiotic concentration in aspirates via liquid chromatography with tandem mass spectrometry (LC-MS/MS) from the middle ear of selected subjects with CSOM who are prescribed and instructed to self-administer ototopical ciprofloxacin. Enrolled subjects will be asked to return 3 to 10 days after initial visit to aspirate the middle ear and receive a follow-up evaluation. Furthermore, the subjects will be asked to keep logs of their medication use and to administer the ototopical medication one hour prior to their appointments. The measured ciprofloxacin concentrations will be correlated with clinical outcomes, primarily the time to symptom resolution. The guiding hypothesis is that patient self-administration of ciprofloxacin drops vary in antibiotic delivery with diluted concentrations significantly below the in vitro concentration of the prescribed solution and that these concentrations are below the bactericidal concentration of ciprofloxacin-resistant bacteria.

Registry
clinicaltrials.gov
Start Date
July 5, 2022
End Date
July 14, 2022
Last Updated
2 years ago
Study Type
Observational
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

James E. Saunders

Professor of Otology / Neurotology

Dartmouth-Hitchcock Medical Center

Eligibility Criteria

Inclusion Criteria

  • Adult patients greater than or equal to 18 years of age
  • Diagnosis of Chronic Suppurative Otitis Media (CSOM)

Exclusion Criteria

  • Atypical presentation of CSOM or atypical anatomy of the ear
  • Presence of additional ear pathophysiology beyond CSOM
  • Adults unable to consent
  • Individuals who are not yet adults (infants, children, teenagers)
  • Pregnant women
  • Prisoners
  • Non-English speaking

Outcomes

Primary Outcomes

Concentration of Ciprofloxacin

Time Frame: 3 to 10 days after initial visit

Antibiotic Delivery to the Middle Ear will be measured by Ciprofloxacin concentration Relevant concentration range is 2000 ng/mL to 2,000,000 ng/mL, which are the minimum inhibitory concentration and theoretical maximum concentration, respectively. Measured through LC-MS/MS, aspirate collected 3-10 days after initial visit.

Secondary Outcomes

  • Patient Compliance to Treatment as measured by Daily Compliance + Symptom Log(Starting after the initial visit, for 10 days)
  • Persistence of Symptoms as measured by Daily Compliance + Symptom Log(Starting after the initial visit, for 10 days. Afterwards, weekly surveys to monitor symptoms for a maximum followup of 12 weeks.)

Study Sites (1)

Loading locations...

Similar Trials